http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-112012009296-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_47ed95899ff396a6554a96521b5e190d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2010-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04a0a9eb52d303c91a57d37fa4a8e761 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_601d93e7ff49183f274b3c0534f96b9b |
| publicationDate | 2021-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-112012009296-A2 |
| titleOfInvention | methods to determine the level or state of activation of an oncogenic fusion protein, to optimize therapy and / or to reduce toxicity in a subject having cancer, to select an appropriate anti-cancer drug for the treatment of a cancer, to identify the response of a cancer to treatment with a cancer drug, to identify the response of a cancer to treatment with an anti-cancer drug, to predict the response of a subject having cancer to treatment with an anti-cancer drug, and to determine whether a subject having cancer is resistant to treatment with an anti-cancer drug. |
| abstract | methods to determine the level or state of activation of an oncogenic fusion protein, to optimize therapy and / or to reduce toxicity in a subject having cancer, to select an appropriate anti-cancer drug for the treatment of a cancer, to identify the response from a cancer to treatment with an anti-cancer drug, to predict the response of a subject having cancer to treatment with an anti-cancer drug, and to determine without a subject having cancer is resistant to treatment with an anti-cancer drug. the present invention provides antibody-based arrangements for detecting the activation state and / or total amount of one or a plurality of oncogenic fusion proteins in a biological sample, such as whole blood or tumor tissue, and methods of using these. in certain examples, the activation state and or the total amount of oncogenic fusion protein (s) present in a sample can be measured in combination with one or a plurality of signal transduction molecules. the compositions and methods of the present invention have the advantages of specificity associated with enzyme linked immunosorbent assays, sensitivity associated with signal amplification, and high-performance multiplexing associated with microarrays. |
| priorityDate | 2009-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1007.